Role of dopamine D2 receptors for antipsychotic activity

Handbook of Experimental Pharmacology

Volumn 212, Issue , 2012, Pages 27-52

  Ginovart, Nathalie ^a   Kapur, Shitij ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic drugs; Dopamine receptor; PET imaging; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE; DOPAMINE RECEPTOR BLOCKING AGENT;

AKATHISIA; ANHEDONIA; ANTIPSYCHOTIC ACTIVITY; DISEASE ACTIVITY; DOPAMINE METABOLISM; DOPAMINE RECEPTOR BLOCKING; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TREATMENT FAILURE; DYSPHONIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIMBIC SYSTEM; NEGATIVE SYNDROME; NEUROCHEMISTRY; NEUROIMAGING; NEUROMODULATION; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSITIVE SYNDROME; POSTSYNAPTIC POTENTIAL; PRESYNAPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSYCHOLOGY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOM; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; DRUG ANTAGONISM; PHYSIOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84870168817     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-25761-2_2     Document Type: Review

References (192)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767 (Pubitemid 28252654)
2. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97:8104-8109 (Pubitemid 30460780)
3. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719 (Pubitemid 37465776)
4. Agid O, Kapur S, Arenovich T, Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60:1228-1235 (Pubitemid 37494076)
5. Agid O, Seeman P, Kapur S (2006) The "delayed onset" of antipsychotic action - an idea whose time has come and gone. J Psychiatry Neurosci 31:93-100
6. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, Kapur S (2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology 32:1209-1215 (Pubitemid 46788848)
7. Agid O, Kapur S, Warrington L, Loebel A, Siu C (2008) Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res 102:241-248
8. Arvanitis LA, Miller BG (1997) Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The seroquel trial 13 study group. Biol Psychiatry 42:233-246 (Pubitemid 27325811)
9. Awad AG, Voruganti LN (2005) Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatr Scand Suppl 111(427):6-13 (Pubitemid 40780194)
10. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl) 99:463-472 (Pubitemid 19273100)
11. Berridge KC (2007) The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 191:391-431 (Pubitemid 46355895)
12. Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, Frank JA, Pickar D, Weinberger DR (2000) The relationship between dorsolateral prefrontal neuronal Nacetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 22:125-132 (Pubitemid 30016014)
13. Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS (2000) Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 150:132-140 (Pubitemid 30429293)
14. Bose SK, Turkheimer FE, Howes OD, Mehta MA, Cunliffe R, Stokes PR, Grasby PM (2008) Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res 106(2-3):148-155
15. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94:2569-2574 (Pubitemid 27136916)
16. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS (2003) Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 23:5-14 (Pubitemid 36164419)
17. Bristow LJ, Collinson N, Cook GP, Curtis N, Freedman SB, Kulagowski JJ, Leeson PD, Patel S, Ragan CI, Ridgill M, Saywell KL, Tricklebank MD (1997) L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther 283:1256-1263 (Pubitemid 28016501)
18. Brown WD, Taylor MD, Roberts AD, Oakes TR, Schueller MJ, Holden JE, Malischke LM, DeJesus OT, Nickles RJ (1999) FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 53:1212-1218 (Pubitemid 29480078)
19. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155:751-760 (Pubitemid 28252653)
20. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J (2006) D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85:232-244 (Pubitemid 43947535)
21. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389 (Pubitemid 34680462)
22. Burt DR, Creese I, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326-328 (Pubitemid 8076966)
23. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144
24. Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200
25. Carman J, Peuskens J, Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 10:207-213
26. Catafau AM, Corripio I, Perez V, Martin JC, Schotte A, Carrio I, Alvarez E (2006) Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Res 148:175-183 (Pubitemid 44750582)
27. Catafau AM, Penengo MM, Nucci G, Bullich S, Corripio I, Parellada E, Garcia-Ribera C, Gomeni R, Merlo-Pich E (2008) Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J Psychopharmacol 22:882-894
28. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619 (Pubitemid 13045297)
29. Connell PH (1958) Amphetamine psychosis. Oxford University Press, London
30. Copolov DL, Link CG, Kowalcyk B (2000) A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'seroquel') and haloperidol in schizophrenia. Psychol Med 30:95-105 (Pubitemid 30099122)
31. Correll CU, Schenk EM (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21:151-156 (Pubitemid 351339869)
32. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM (2003) Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 160:2063-2065 (Pubitemid 39619650)
33. Corrigan MH, Gallen CC, Bonura ML, Merchant KM (2004) Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial. Biol Psychiatry 55:445-451 (Pubitemid 38338530)
34. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481-483
35. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C, Artiges E, Feline A, Syrota A, Martinot JL (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23:167-174 (Pubitemid 27106901)
36. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148:1474-1486
37. Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:553-564 (Pubitemid 36682312)
38. Day JJ, Roitman MF, Wightman RM, Carelli RM (2007) Associative learning mediates dynamic shifts in dopamine signaling in the nucleus accumbens. Nat Neurosci 10:1020-1028 (Pubitemid 47185195)
39. Diaconescu AO, Jensen J, Wang H, Willeit M, Menon M, Kapur S, McIntosh AR (2011) Aberrant effective connectivity in schizophrenia patients during appetitive conditioning. Front Hum Neurosci 4:239. doi:10.3389/fnhum.2010.00239
40. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ (2000) 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 100:1-11
41. Farde L, Wiesel FA, Hall H, Halldin C, Stone-Elander S, Sedvall G (1987) No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 44:671-672
42. Farde L, Wiesel FA, Nordstrom AL, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 99: S28-S31 (Pubitemid 19244135)
43. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
44. Gardner EL, Seeger TF (1983) Neurobehavioral evidence for mesolimbic specificity of action by clozapine: studies using electrical intracranial self-stimulation. Biol Psychiatry 18:1357-1362 (Pubitemid 14223437)
45. Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R (1998) Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 135:119-126 (Pubitemid 28055494)
46. Ginovart N (2005) Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism. Mol Imaging Biol 7:45-52 (Pubitemid 41348875)
47. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S (2009) D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 34:662-671
48. Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, Friberg L, Baare W, Hemmingsen R, Videbaek C (2006) Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 60:621-629 (Pubitemid 44402367)
49. Goldberg SC (1985) Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11:453-456 (Pubitemid 15036188)
50. Goldstein JM (1999) Quetiapine fumarate (seroquel): a new atypical antipsychotic. Drugs Today (Barc) 35:193-210 (Pubitemid 29238943)
51. Goldstein JM (2000) The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacol 3:339-349 (Pubitemid 32056629)
52. Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993) Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 112:293-298 (Pubitemid 23278292)
53. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24
54. Grace AA, Bunney BS, Moore H, Todd CL (1997) Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci 20:31-37 (Pubitemid 26421230)
55. Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, Rusjan P, Houle S, Wilson AA, Kapur S (2009a) The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study with [11C]-(+)-PHNO. Arch Gen Psychiatry 66:606-615
56. Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Barsoum P, Rusjan P, Wilson AA, Zipursky R, Kapur S (2009b) The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 34:1078-1086
57. Gross G, Drescher K (2012) The role of dopamine D3 receptors for antipsychotic activity and cognitive functions. In: Gross G, Geyer M (eds) Handbook of Experimental Pharmacology, vol 213. Current Antipsychotics. Springer, Heidelberg
58. Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rosch F, Schaefer WM, Vernaleken I (2008) Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F] fallypride PET study. Am J Psychiatry 165(8):988-995
59. Hand TH, Hu XT, Wang RY (1987) Differential effects of acute clozapine and haloperidol on the activity of ventral tegmental (A10) and nigrostriatal (A9) dopamine neurons. Brain Res 415:257-269 (Pubitemid 17100331)
60. Haro JM, Salvador-Carulla L (2006) The SOHO (schizophrenia outpatient health outcome) study: implications for the treatment of schizophrenia. CNS Drugs 20:293-301
61. Haro JM, Novick D, Suarez D, Roca M (2009) Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res 43(3):265-273
62. Hellewell JS (1999) Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 60(Suppl 23):14-19
63. Hertel P (2006) Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse 60:543-552 (Pubitemid 44537087)
64. Hietala J, Syvalahti E, Vuorio K, Nagren K, Lehikoinen P, Ruotsalainen U, Rakkolainen V, Lehtinen V, Wegelius U (1994) Striatal D2 dopamine receptor characteristics in neurolepticnaive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51:116-123 (Pubitemid 24054313)
65. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Kirvela O, Ruotsalainen U et al (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346:1130-1131
66. Hietala J, Syvalahti E, Vilkman H, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M, Solin O, Kuoppamaki M, Eronen E, Ruotsalainen U, Salokangas RK (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35:41-50 (Pubitemid 29023553)
67. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 35:549-562
68. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66:13-20
69. Ito H, Arakawa R, Takahashi H, Takano H, Okumura M, Otsuka T, Ikoma Y, Shidahara M, Suhara T (2009) No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. Int J Neuropsychopharmacol 12(5):667-675
70. Jauss M, Schroder J, Pantel J, Bachmann S, Gerdsen I, Mundt C (1998) Severe akathisia during olanzapine treatment of acute schizophrenia. Pharmacopsychiatry 31:146-148 (Pubitemid 28399085)
71. Jensen J, Willeit M, Zipursky RB, Savina I, Smith AJ, Menon M, Crawley AP, Kapur S (2008) The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 33:473-479
72. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second-vs firstgeneration antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079-1087 (Pubitemid 44498387)
73. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
74. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771
75. Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13-23 (Pubitemid 36042420)
76. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090 (Pubitemid 37464954)
77. Kapur S, Remington G (2001a) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503-517 (Pubitemid 32195338)
78. Kapur S, Remington G (2001b) Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873-883 (Pubitemid 34020700)
79. Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S (1997) PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 154:1525-1529 (Pubitemid 27471344)
80. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928 (Pubitemid 28307604)
81. Kapur S, Zipursky RB, Remington G (1999) Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293 (Pubitemid 29077120)
82. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000a) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520 (Pubitemid 30191189)
83. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000b) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559 (Pubitemid 30349435)
84. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129-1134 (Pubitemid 34920235)
85. Kapur S, Mizrahi R, Li M (2005) From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 79:59-68 (Pubitemid 41362593)
86. Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159:761-767 (Pubitemid 34465049)
87. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33:3111-3125
88. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2005) Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30:2283-2289 (Pubitemid 41643981)
89. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31:1991-2001
90. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY (2009) Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry 65:1024-1031
91. Kestler LP, Walker E, Vega EM (2001) Dopamine receptors in the brains of schizophrenia patients: a meta-analysis of the findings. Behav Pharmacol 12:355-371 (Pubitemid 32983509)
92. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, Kane JM (2008) Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 102:230-240
93. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM (2011) Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35(2):581-590. doi:10.1038/npp. 2009.164
94. Knable MB, Heinz A, Raedler T, Weinberger DR (1997) Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res 75:91-101 (Pubitemid 27435975)
95. Kramer MS, Last B, Getson A, Reines SA (1997) The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 dopamine antagonist group. Arch Gen Psychiatry 54:567-572 (Pubitemid 27258555)
96. Kuhar MJ, Joyce AR (2001) Slow onset of CNS drugs: can changes in protein concentration account for the delay? Trends Pharmacol Sci 22:450-456 (Pubitemid 32816936)
97. Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Gründer G (2007) Elevated [18 F]fluorodopamine turnover in brain of patients with schizophrenia: an [18 F]fluorodopa/positron emission tomography study. J Neurosci 27:8080-8087 (Pubitemid 47173328)
98. Lambert M, Schimmelmann BG, Karow A, Naber D (2003) Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance. Pharmacopsychiatry 36(Suppl 3):S181-S190 (Pubitemid 38085135)
99. Lambert M, Schimmelmann BG, Schacht A, Suarez D, Haro JM, Novick D, Wagner T, Wehmeier PM, Huber CG, Hundemer HP, Dittmann RW, Naber D (2011) Differential 3-year effects of first-versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models. J Clin Psychopharmacol 31:226-230
100. Lane RF, Blaha CD, Rivet JM (1988) Selective inhibition of mesolimbic dopamine release following chronic administration of clozapine: involvement of alpha 1-noradrenergic receptors demonstrated by in vivo voltammetry. Brain Res 460:398-401
101. Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42:211-221 (Pubitemid 28529874)
102. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451 (Pubitemid 30164887)
103. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93:9235-9240
104. Lee T, Seeman P, Tourtellotte WW, Farley IJ, Hornykeiwicz O (1978) Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274:897-900 (Pubitemid 9004058)
105. Lemmens P, Brecher M, Van Baelen B (1999) A combined analysis of double-blind studies with risperidone vs. Placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 99:160-170 (Pubitemid 29118258)
106. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51-68 (Pubitemid 29023554)
107. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005) Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543-1549 (Pubitemid 40805384)
108. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41
109. Levant B (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252 (Pubitemid 27414914)
110. Lewander T (1994) Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl 380:8-13 (Pubitemid 24147813)
111. Lieberman JA, Kane JM, Johns CA (1989) Clozapine: guidelines for clinical management. J Clin Psychiatry 50:329-338 (Pubitemid 19239055)
112. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223 (Pubitemid 41345943)
113. Lindstrom LH, Gefvert O, Hagberg G, Lundberg T, Bergstrom M, Hartvig P, Langstrom B (1999) Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 46:681-688 (Pubitemid 29401864)
114. Ljungberg T, Ungerstedt U (1985) A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol Biochem Behav 23:479-485 (Pubitemid 16256920)
115. Lomena F, Catafau AM, Parellada E, Bernardo M, Font M, Gutierrez F, Pavia J (2004) Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: an 123I-IBZM-SPECT study. Psychopharmacology (Berl) 172:165-169 (Pubitemid 38388765)
116. Luft B, Taylor D (2006) A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother 7:1739-1748
117. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164:1411-1417 (Pubitemid 47461142)
118. Marder SR (2005) Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl 111(427):43-46 (Pubitemid 40780199)
119. McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA (2011) The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology 35(8):1826-1835. doi:10.1038/npp. 2010.50
120. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P (2004) Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 61:134-142 (Pubitemid 38146547)
121. Meltzer HY (2004) What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 4:53-57 (Pubitemid 38145838)
122. Meltzer HY, Matsubara S, Lee JC (1989) The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390-392 (Pubitemid 20260244)
123. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172 (Pubitemid 37464960)
124. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 5:267-271 (Pubitemid 34171141)
125. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760
126. Möller HJ, Riedel M, Jager M, Wickelmaier F, Maier W, Kuhn KU, Buchkremer G, Heuser I, Klosterkötter J, Gastpar M, Braus DF, Schlosser R, Schneider F, Ohmann C, Riesbeck M, Gaebel W (2008) Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German research network on schizophrenia. Int J Neuropsychopharmacol 11:985-997
127. Morken G, Widen JH, Grawe RW (2008) Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 8:32
128. Murray GK, Corlett PR, Clark L, Pessiglione M, Blackwell AD, Honey G, Jones PB, Bullmore ET, Robbins TW, Fletcher PC (2008) Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol Psychiatry 13(239):267-276 (Pubitemid 351272654)
129. Naber D, Karow A, Lambert M (2005) Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl 111(427):29-34 (Pubitemid 40780197)
130. Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1-93 (Pubitemid 40677047)
131. Nordstrom AL, Farde L, Halldin C (1992) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 106:433-438
132. Nordstrom AL, Farde L, Eriksson L, Halldin C (1995) No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C] N-methylspiperone. Psychiatry Res 61:67-83
133. Nordstrom AL, Nyberg S, Olsson H, Farde L (1998) Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch Gen Psychiatry 55:283-284
134. Nozaki S, Kato M, Takano H, Ito H, Takahashi H, Arakawa R, Okumura M, Fujimura Y, Matsumoto R, Ota M, Takano A, Otsuka A, Yasuno F, Okubo Y, Kashima H, Suhara T (2009) Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res 108:78-84
135. Nyberg S, Olsson H, Nilsson U, Maehlum E, Halldin C, Farde L (2002) Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology (Berl) 162:37-41 (Pubitemid 34639554)
136. O'Connor SE, Brown RA (1982) The pharmacology of sulpiride - a dopamine receptor antagonist. Gen Pharmacol 13:185-193 (Pubitemid 12121874)
137. Oakley NR, Hayes AG, Sheehan MJ (1991) Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigro-striatal dopaminergic pathways in the rat. Psychopharmacology (Berl) 105:204-208
138. Owen F, Cross AJ, Waddington JL, Poulter M, Gamble SJ, Crow TJ (1980) Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration. Life Sci 26:55-59 (Pubitemid 10126848)
139. Pae CU, Kim JJ, Lee CU, Lee SJ, Lee C, Patkar AA, Masand PS, Paik IH (2007) Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallelgroup trial. J Clin Psychiatry 68:399-405 (Pubitemid 46506804)
140. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107 (Pubitemid 47517511)
141. Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppa T, Harkanen T, Koskinen S, Lonnqvist J (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64:19-28 (Pubitemid 46041735)
142. Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kerwin RW (1994) D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 164:16-26
143. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997) Limbic selectivity of clozapine. Lancet 350:490-491
144. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 91:11651-11654 (Pubitemid 24356402)
145. Remington G, Seeman P, Shammi C, Mann S, Kapur S (2005) "Extended" antipsychotic dosing: rationale and pilot data. J Clin Psychopharmacol 25:611-613 (Pubitemid 41669063)
146. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S (2011) "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebocontrolled trial. J Clin Psychiatry 72(8):1042-1048. doi:10.4088/JCP.09m05866yel
147. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241-247 (Pubitemid 29125132)
148. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA (2002) Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res 57:209-219 (Pubitemid 35240023)
149. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J (2006) Cost-effectiveness of secondgeneration antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 163:2080-2089 (Pubitemid 46114227)
150. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995) D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl) 120:365-368
151. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007) "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986 (Pubitemid 46438984)
152. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 64:145-152
153. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97 (Pubitemid 27171391)
154. Schooler NR (1994) Deficit symptoms in schizophrenia: negative symptoms versus neurolepticinduced deficits. Acta Psychiatr Scand Suppl 380:21-26 (Pubitemid 24147815)
155. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73 (Pubitemid 26112775)
156. Schultz W (2006) Behavioral theories and the neurophysiology of reward. Annu Rev Psychol 57:87-115 (Pubitemid 43237228)
157. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133-152 (Pubitemid 17119661)
158. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38 (Pubitemid 34302921)
159. Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217-1219
160. Seeman P, Ulpian C, Bergeron C, Riederer P, Jellinger K, Gabriel E, Reynolds GP, Tourtellotte WW (1984) Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225:728-731
161. Seeman P, Weinshenker D, Quirion R, Srivastava LK, Bhardwaj SK, Grandy DK, Premont RT, Sotnikova TD, Boksa P, El-Ghundi M, O'Dowd BF, George SR, Perreault ML, Mannisto PT, Robinson S, Palmiter RD, Tallerico T (2005) Dopamine supersensitivity correlates with D2high states, implying many paths to psychosis. Proc Natl Acad Sci U S A 102:3513-3518 (Pubitemid 40328076)
162. Skarsfeldt T (1988) Differential effects after repeated treatment with haloperidol, clozapine, thioridazine and tefludazine on SNC and VTA dopamine neurones in rats. Life Sci 42:1037-1044 (Pubitemid 18056840)
163. Skarsfeldt T, Perregaard J (1990) Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur J Pharmacol 182:613-614 (Pubitemid 20260788)
164. Small JG, Kolar MC, Kellams JJ (2004) Quetiapine in schizophrenia: onset of action within the first week of treatment. Curr Med Res Opin 20:1017-1023 (Pubitemid 38954464)
165. Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Saf 22:195-214 (Pubitemid 30157580)
166. Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Kerwin RW, Pilowsky LS (2000) Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 177:408-415
167. Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97-105
168. Strange PG (2001) Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53:119-133 (Pubitemid 32173111)
169. Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T, Nakashima Y, Nakayama K, Tanada S, Suzuki K, Halldin C, Farde L (2002) Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59:25-30 (Pubitemid 34044401)
170. Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L (2001) No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 158:926-930 (Pubitemid 32547623)
171. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L (2003) Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 6:361-370 (Pubitemid 38146254)
172. Talvik M, Nordstrom AL, Okubo Y, Olsson H, Borg J, Halldin C, Farde L (2006) Dopamine D2 receptor binding in drug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 148:165-173 (Pubitemid 44750590)
173. Tamminga CA (2002) Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109:411-420 (Pubitemid 34251643)
174. Tarsy D, Baldessarini RJ (1977) The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 12:431-450 (Pubitemid 8122067)
175. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-321 (Pubitemid 34280640)
176. Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, Epstein I, Christensen BK, Zipursky RB (2002) Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 63:992-997 (Pubitemid 35388057)
177. Tort AB, Souza DO, Lara DR (2005) On the simulation of the time-course of dopamine D2 receptor occupancy from the pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 8:137-139 (Pubitemid 40388822)
178. Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL (1998) Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 155:505-508 (Pubitemid 28207446)
179. Tsuang M (2000) Schizophrenia: genes and environment. Biol Psychiatry 47:210-220 (Pubitemid 30077397)
180. Tune LE, Wong DF, Pearlson G, Strauss M, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J et al (1993) Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res 49:219-237
181. Turrone P, Remington G, Kapur S, Nobrega JN (2003) Differential effects of within-day continuous vs. Transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats. Neuropsychopharmacology 28:1433-1439 (Pubitemid 41070877)
182. van Rossum JM (1966) The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 160:492-494
183. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614 (Pubitemid 21912282)
184. Vernaleken I, Janouschek H, Raptis M, Hellmann S, Veselinovic T, Brocheler A, Boy C, Cumming P, Hiemke C, Rosch F, Schafer WM, Gründer G (2011) Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int J Neuropsychopharmacol 13 (7):951-960. doi:10.1017/S1461145710000374
185. Voruganti L, Awad AG (2004) Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 171:121-132 (Pubitemid 38134648)
186. Walker E, Kestler L, Bollini A, Hochman KM (2004) Schizophrenia: etiology and course. Annu Rev Psychol 55:401-430 (Pubitemid 40517789)
187. White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057 (Pubitemid 13041955)
188. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Toung JK, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558-1563 (Pubitemid 17125279)
189. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc HC, Maziere B, Paillere-Martinot ML (2001) Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179:503-508 (Pubitemid 34031674)
190. Yang YK, Yu L, Yeh TL, Chiu NT, Chen PS, Lee IH (2004) Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 161:1496-1498 (Pubitemid 38989108)
191. Youngren KD, Inglis FM, Pivirotto PJ, Jedema HP, Bradberry CW, Goldman-Rakic PS, Roth RH, Moghaddam B (1999) Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20:403-412 (Pubitemid 29123868)
192. Zakzanis KK, Hansen KT (1998) Dopamine D2 densities and the schizophrenic brain. Schizophr Res 32:201-206